Dose-related antibody responses to purified Vero cell rabies vaccine in healthy Thai children

被引:0
|
作者
Chanthavanich, P [1 ]
Sabchareon, A [1 ]
Singhasivanon, V [1 ]
Pojjaroen-Anant, C [1 ]
Chongsuphajaisiddhi, T [1 ]
Kittikoon, P [1 ]
机构
[1] Mahidol Univ, Fac Trop Med, Dept Trop Pediat, Bangkok 10400, Thailand
来源
关键词
PVRV; dose-related; children;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
To study whether the response to tissue culture rabies vaccine in children is dose related, 82 children aged 7-13 years (mean: 9.5 years), weighing 17-40 kg (mean: 25 kg), were divided randomly into three groups. All of the children received purified Vero cell rabies vaccine 2-1-1 intramuscular regimen (two sites on day 0, one site each on days 7 and 21). Group I (n = 29) received a full dose of 0.5 mt (antigenic value: 7.1 international units [IU]/dose), group II (n = 26) received a half dose of 0.25 mL (antigenic value: 3.55 IU/dose), and group III (n = 27) received a one-third dose of 0.15 mL (antigenic value: 2.13 IU/dose). The rapid fluorescent focus inhibition test (RFFIT) was used to measure the neutralizing antibody (Nab). The results showed that all of the children seroconverted (> 0.5 IU/mL) on day 14. The Nab responses were dose related. The geometric mean titers (GMT) on days 14, 28, 91, and 182 of group I were 23 (range: 4-134), 18 (range: 3-86), 3 (range: 1-25), and 1 (range. < 0.5-18) IU/mL, respectively. The GMT values of group II on the corresponding days were 20 (range: 5-186), 11 (range: 3-159), 1 (range: 0.5-14), and 1 (range: < 0.5-9) IU/mL. Although the Nab levels in group II were lower than those in group I, the differences were not statistically significant. The GMT of group III on days 14 and 28, which were 6 (range: 0.5-29) and 7 (range: 1-29) IU/mL, were significantly lower than those of groups I and II (P < 0.05). However, the GMT on days 91 and 182 of group III, 1 (range: < 0.5-10) and 0.5 (range: < 0.5-7) IU/mL, were not significantly different from those of groups I and II. In conclusion, when antigenic value of rabies vaccine is less than 2.5 IU/dose (group III), the immune response is relatively poor. The doses of rabies post-exposure vaccination in children should not be reduced.
引用
收藏
页码:97 / 100
页数:4
相关论文
共 50 条
  • [21] Persistence of antibodies in children after intradermal or intramuscular administration of preexposure Primary and booster immunizations with purified Vero cell rabies vaccine
    Sabchareon, A
    Chantavanich, P
    Pasuralertsakul, S
    Pojjaroen-Anant, C
    Prarinyanupharb, V
    Attanath, P
    Singhasivanon, V
    Buppodom, W
    Lang, J
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (11) : 1001 - 1007
  • [22] Antibody persistence upto 5 years after primary immunization and booster with an inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children
    Hattasingh, Weerawan
    Chanthavanich, Pornthep
    Sirivichayakul, Chukiat
    Arunsodsai, Watcharee
    Surangsrirat, Surachai
    Srisuwannaporn, Termsang
    Kaewma, Benjawan
    Yoksan, Sutee
    Limkittikul, Kriengsak
    Yang, Junwei
    Mao, Yu
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (01)
  • [23] Safety of purified Vero cell rabies vaccine manufactured in Pakistan: a comparative analysis of intradermal and intramuscular routes
    Ali, Waqar
    Tajik, Mohammad Ismail
    Ali, Iftikhar
    Gul, Alia
    Khan, Jehan Zeb
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (05) : 789 - 796
  • [24] Purified Vero cell rabies vaccine (PVRV, Verorab): A review of intradermal use between 1985 and 2019
    Moulenat, T.
    Castells, V. Bosch
    Houillon, G.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 101 : 530 - 530
  • [25] Production and evaluation of a chromatographically purified Vero cell rabies vaccine (PVRV) in China using microcarrier technology
    Yu, Pengcheng
    Huang, Ying
    Zhang, Yibin
    Tang, Qing
    Liang, Guodong
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (09) : 1230 - 1235
  • [26] Immunogenicity of purified Vero cell rabies vaccine used in the treatment of fox-bite victims in India
    Matha, IS
    Salunke, SR
    CLINICAL INFECTIOUS DISEASES, 2005, 40 (04) : 611 - 613
  • [27] Safety and immunogenicity of chromatographically purified Vero cell rabies vaccine for intradermal pre- and post-exposure rabies prophylaxis
    Tantawichien, Terapong
    Sibunruang, Suda
    Tantawichien, Thanphet
    Angsanakul, Jaruboot
    Benjavongkulchai, Maneerat
    Limsuwan, Kornvika
    Udomchaisakul, Piyada
    Khomvilai, Sumana
    Sitprija, Visith
    EXPERT REVIEW OF VACCINES, 2014, 13 (12) : 1593 - 1601
  • [28] Safety and neutralizing rabies antibody in healthy subjects given a single dose of rabies immune globulin caprylate/chromatography purified
    Hanna, Kim
    Cruz, Maria Cristina
    Mondou, Elsa
    Corsi, Edward
    Vandeberg, Peter
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2018, 10 : 79 - 88
  • [29] A comparative study on the safety and immunogenicity of purified duck embryo cell vaccine (PDEV, Vaxirab) with purified chick embryo cell vaccine (PCEC, Rabipur) and purifed vero cell rabies vaccine (PVRV, Verorab)
    Ashwathnarayana, Doddabele Hanumantaiah
    Madhusudana, Shampur Narayana
    Sampath, Gadey
    Sathpathy, Durga Madhab
    Mankeshwar, Ranjit
    Ravish, Haradana Halli Shankariah
    Ullas, Padinjaremattathil Thankappan
    Behra, Tapas Ranjan
    Sudarshan, Mysore Kalappa
    Gangaboraiah
    Shamanna, Manjula
    VACCINE, 2009, 28 (01) : 148 - 151
  • [30] Purified Vero Cell Rabies Vaccine (PVRV, Verorab®): A Systematic Review of Intradermal Use Between 1985 and 2019
    Moulenat, Thomas
    Petit, Celine
    Castells, Valerie Bosch
    Houillon, Guy
    TROPICAL MEDICINE AND INFECTIOUS DISEASE, 2020, 5 (01)